In COVID-19 clinical update #110, Dr. Griffin covers hospital admissions during variant outbreaks, viral load in vaccinated and unvaccinated individuals, predictive capacity of symptoms in children, comparison of antigen tests, incidence of myocarditis after vaccination, steroids during replication phase, Paxlovid efficacy and safety, fluvoxamine, sabizabutin, colchicine, and prevalence of infection in Africa.
Click arrow to play
Download TWiV 889 (52 MB .mp3, 53 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Hospital admissions during Omicron and Delta variant outbreaks (Lancet) 3:48
- Viral load in unvaccinated and vaccinated individuals (Nat Med) 6:19
- Predictive Capability of symptoms in children (Clin Inf Dis) 11:59
- Comparison of antigen tests (medRxiv) 12:26
- Incidence of Myocarditis after COVID19 and non-COVID19 vaccination (Lancet) 22:00
- Steroids during viral replication phase (Resp)
- Paxlovid efficacy and safety (Pfizer) 32:33
- Fluvoxamine & Outpatient Management (JAMA) 33:06
- Sabizabutin efficacy and safety (Veru) 37:14
- Colchicine and lack of benefit (Lancet) 40:56
- SARS-CoV-2 prevalence in Africa (medRxiv) 42:05
- Contribute to ASTMH fundraiser at PWB 44:13
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 889 44:59
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
Good morning Professor Racinello,
Good update from Daniel on the YouTube, but download links are going to TWiV 886 at the moment. Lookiy forward to 889 going up on the download so I can put it on my phone to enjoy again.
Dr Griffin. I am a 70 yo retired Family Physician who has fully enjoyed and learned much from both your weekly briefing and all the TWIV podcasts What is happening to Novavax in the USA. It has been approved in 39 other countries, why has it taken so long for this approval process. This protein subunit vaccine would likely be more acceptable to those hesitant to have the perceived “experimental “ RNA vaccines with very similar efficacy and severe disease prevention. I am hoping it will be approved by fall so that I may have this as a choice for my 2nd booster. Thanks so much for all the hard work you all have done and the efforts to improve and distribute public health education, Dudley Gordon. MD